Mesenchymal stromal cells and uses related thereto
AssigneeAstellas Institute for Regenerative Medicine
InventorsErin Anne Kimbrel, Robert P. Lanza, Jianlin Chu, Nicholas Arthur Kouris
Life of this patent
Estimating the term…
Abstract
The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and method sof treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.
Claims21
-125. (canceled)
A pharmaceutical preparation, comprising at least 106 human mesenchymal stromal cells, wherein basal CD24 expression is upregulated in mesenchymal stromal cells of the preparation, as compared to mesenchymal stromal cells of bone marrow, and wherein a basal level of mRNA encoding interleukin-6 (IL-6) expressed in mesenchymal stromal cells of the preparation is less than ten percent of a basal level of mRNA encoding IL-6 expressed in mesenchymal stromal cells of bone marrow.
A pharmaceutical preparation comprising human mesenchymal stromal cells generated in vitro from hemangioblasts obtained from pluripotent cells in the absence of EPO.
A method for generating human mesenchymal stromal cells comprising
- obtaining hemangioblasts from human pluripotent stem cells in the absence of EPO;
- differentiating the hemangioblasts to produce a mesenchymal stromal cell population wherein basal CD24 expression is upregulated in mesenchymal stromal cells of the population, as compared to mesenchymal stromal cells of bone marrow, and wherein a basal level of mRNA encoding interleukin-6 (IL-6) is expressed in mesenchymal stromal cells of the population at a level that is less than ten percent of a basal level of mRNA encoding IL-6 in mesenchymal stromal cells of bone marrow;
- and
- isolating the mesenchymal stromal cell population.
Dependencies are inferred from the claim text.